Search Within

Michael Morris

  1. "Konrad Stopsack"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (14)
  2. Genitourinary Oncology Service (14)
  3. Sloan Kettering Institute Postdocs (14)
  4. Solid Tumor Oncology Division (14)
  5. GSK Faculty (9)
  6. Human Oncology and Pathogenesis Program (9)

More Groups

People
  1. Konrad Stopsack (14)
  2. Philip Kantoff (13)
  3. Wassim Abida (12)
  4. Howard Scher (10)
  5. Dana Rathkopf (8)
  6. Daniel Danila (8)

More People

Years
  1. 2025 (2)
  2. 2024 (1)
  3. 2022 (4)
  4. 2021 (2)
  5. 2020 (4)
  6. 2019 (1)
Publications
  1. Clinical Cancer Research (6)
  2. Journal of Clinical Oncology (2)
  3. Cancer Research (1)
  4. Cell Reports (1)
  5. European Urology (1)
  6. JCO Precision Oncology (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (3)
  3. Cell Press (1)
  4. Elsevier Science, Inc. (1)
  5. John Wiley & Sons (1)
  6. Oxford University Press (1)

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways
    Journal Article

    Hirani, R.; Nandakumar, S.; Zaman, N.; Prabhakaraalva, P.; King, S. A.; Kalidindi, T. M.; Ghale, R.; Rajanala, S. H.; Fidele, D. C.; De Stanchina, E.; more...
    Cell Reports (2025)

    Fulltext@MSK | Save
  • Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer
    Journal Article

    Stopsack, K. H.; Vijai, J.; Conry, M.; Berchuck, J. E.; Kemel, Y.; Vasselman, S. E.; Freeman, D. A.; Lee, G. S. M.; Mandelker, D.; Solit, D. B.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer
    Journal Article

    Lenis, A. T.; Ravichandran, V.; Brown, S.; Alam, S. M.; Katims, A.; Truong, H.; Reisz, P. A.; Vasselman, S.; Nweji, B.; Autio, K. A.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer
    Journal Article

    Chakraborty, G.; Nandakumar, S.; Hirani, R.; Nguyen, B.; Stopsack, K. H.; Kreitzer, C.; Rajanala, S. H.; Ghale, R.; Mazzu, Y. Z.; Pillarsetty, N. V. K.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Journal Article

    Keegan, N. M.; Vasselman, S. E.; Barnett, E. S.; Nweji, B.; Carbone, E. A.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Prostate (2022)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Meeting Abstract

    Keegan, N. M.; Vasselman, S. E.; Barnett, E.; Nweji, B.; Carbone, E.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Inferences about drug safety in phase III trials in oncology: Examples from advanced prostate cancer
    Journal Article

    Drago, J. Z.; Gönen, M.; Thanarajasingam, G.; Sacks, C. A.; Morris, M. J.; Kantoff, P. W.; Stopsack, K. H.
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors
    Journal Article

    Chakraborty, G.; Khan Patail, N.; Hirani, R.; Nandakumar, S.; Mazzu, Y. Z.; Yoshikawa, Y.; Atiq, M.; Jehane, L. E.; Stopsack, K. H.; Lee, G. S. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • CDK12 alterations define a distinct molecular subtype of prostate cancers with unique genomic and clinical characteristics
    Meeting Abstract

    Nguyen, B.; Mota, J. M.; Nandakumar, S.; Stopsack, K. H.; Weg, E.; Rathkopf, D.; Morris, M. J.; Scher, H.; Kantoff, P. W.; Gopalan, A.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save